Logo image of GENX.CA

GENIX PHARMACEUTICALS CORP (GENX.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:GENX - CA37232A1093 - Common Stock

0.025 CAD
0 (-16.67%)
Last: 11/21/2025, 7:00:00 PM
Fundamental Rating

0

Overall GENX gets a fundamental rating of 0 out of 10. We evaluated GENX against 3 industry peers in the Personal Care Products industry. GENX has a bad profitability rating. Also its financial health evaluation is rather negative. GENX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GENX had negative earnings in the past year.
In the past year GENX has reported a negative cash flow from operations.
In the past 5 years GENX always reported negative net income.
In the past 5 years GENX always reported negative operating cash flow.
GENX.CA Yearly Net Income VS EBIT VS OCF VS FCFGENX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -327.68%, GENX is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -327.68%
ROE N/A
ROIC N/A
ROA(3y)-717.5%
ROA(5y)-440.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GENX.CA Yearly ROA, ROE, ROICGENX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

GENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENX.CA Yearly Profit, Operating, Gross MarginsGENX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

GENX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GENX has about the same amount of shares outstanding.
The number of shares outstanding for GENX has been increased compared to 5 years ago.
Compared to 1 year ago, GENX has a worse debt to assets ratio.
GENX.CA Yearly Shares OutstandingGENX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GENX.CA Yearly Total Debt VS Total AssetsGENX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

GENX has an Altman-Z score of -664.26. This is a bad value and indicates that GENX is not financially healthy and even has some risk of bankruptcy.
GENX has a Altman-Z score of -664.26. This is in the lower half of the industry: GENX underperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -664.26
ROIC/WACCN/A
WACC6.05%
GENX.CA Yearly LT Debt VS Equity VS FCFGENX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M

2.3 Liquidity

A Current Ratio of 0.01 indicates that GENX may have some problems paying its short term obligations.
The Current ratio of GENX (0.01) is worse than 66.67% of its industry peers.
A Quick Ratio of 0.01 indicates that GENX may have some problems paying its short term obligations.
GENX has a worse Quick ratio (0.01) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
GENX.CA Yearly Current Assets VS Current LiabilitesGENX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

1

3. Growth

3.1 Past

GENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.78%, which is quite impressive.
GENX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.50%.
Measured over the past years, GENX shows a very negative growth in Revenue. The Revenue has been decreasing by -50.46% on average per year.
EPS 1Y (TTM)97.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-97.5%
Revenue growth 3YN/A
Revenue growth 5Y-50.46%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GENX.CA Yearly Revenue VS EstimatesGENX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2023 2024 200K 400K 600K 800K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
GENX.CA Price Earnings VS Forward Price EarningsGENX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENX.CA Per share dataGENX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0 -0.01 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GENX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENIX PHARMACEUTICALS CORP

TSX-V:GENX (11/21/2025, 7:00:00 PM)

0.025

0 (-16.67%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners33.46%
Ins Owner ChangeN/A
Market Cap1.53M
Revenue(TTM)100
Net Income(TTM)-88.80K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15305
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -327.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-717.5%
ROA(5y)-440.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z -664.26
F-Score2
WACC6.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.5%
Revenue growth 3YN/A
Revenue growth 5Y-50.46%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.35%
OCF growth 3YN/A
OCF growth 5YN/A

GENIX PHARMACEUTICALS CORP / GENX.CA FAQ

Can you provide the ChartMill fundamental rating for GENIX PHARMACEUTICALS CORP?

ChartMill assigns a fundamental rating of 0 / 10 to GENX.CA.


What is the valuation status for GENX stock?

ChartMill assigns a valuation rating of 0 / 10 to GENIX PHARMACEUTICALS CORP (GENX.CA). This can be considered as Overvalued.


What is the profitability of GENX stock?

GENIX PHARMACEUTICALS CORP (GENX.CA) has a profitability rating of 0 / 10.


How financially healthy is GENIX PHARMACEUTICALS CORP?

The financial health rating of GENIX PHARMACEUTICALS CORP (GENX.CA) is 0 / 10.